Add‐on effects of fluvastatin in simeprevir/pegylated‐interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled study
Add‐on effects of fluvastatin in simeprevir/pegylated‐interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled study
复制标题
西美普韦/聚乙二醇干扰素/利巴韦林联合治疗中氟伐他汀对基因 1 型丙型肝炎病毒感染患者的附加作用：一项随机对照研究
作者：
G. Suda;J. Ito;A. Nagasaka;Yoshiya Yamamoto;Ken Furuya;Munenori Okamoto;K. Terashita;Tomoe Kobayashi;I. Tsunematsu;J. Yoshida;T. Meguro;Masatsugu Ohara;N. Kawagishi;M. Kimura;M. Umemura;Takaaki Izumi;Yoko Tsukuda;Masato Nakai;T. Sho;Mitsuteru Natsuizaka;Kenichi Morikawa;Koji Ogawa;N. Sakamoto
日本肝病学会指南指出，丙型肝炎病毒（HCV）蛋白酶抑制剂与西米泼韦（SMV）、聚乙二醇干扰素（Peg‐IFN）和利巴韦林（RBV）联合治疗是对直接直接作用的含抗病毒治疗方案无效的患者的治疗选择。然而，治疗结果仍有改进的余地。在HCV感染患者的Peg-IFN和RBV联合治疗中，氟伐他汀（FLV）添加治疗可显著改善持续病毒学应答（SVR），但FLV对SMV联合治疗的添加作用尚不清楚。
The Japan Society of Hepatology guidelines indicate that hepatitis C virus (HCV) protease inhibitor combination therapy with simeprevir (SMV), pegylated‐interferon (Peg‐IFN), and ribavirin (RBV) is a therapeutic option for patients who fail to respond to a direct direct‐acting antiviral‐containing regimen. However, treatment outcomes have room for improvement. Fluvastatin (FLV) add‐on treatment in Peg‐IFN and RBV combination therapy for HCV‐infected patients significantly improved the sustained virologic response (SVR), but the add‐on effect of FLV on SMV combination therapy is not well understood.
影响因子：
29.4
作者：
Kim, Sun Suk;Peng, Lee F.;Chung, Raymond T.
通讯作者：
Chung, Raymond T.